President Donald Trump on Tuesday announced the U.S. government will purchase 100 million doses of Moderna's experimental coronavirus vaccine, which is currently in late-stage human trials.
Moderna separately said the deal for its vaccine, mRNA-1273, is worth $1.53 billion and will give the federal government the option to purchase up to 400 million additional doses. The U.S. has already invested $955 million in Moderna's vaccine development, bringing its total investment up to $2.48 billion, the company said in a press release Tuesday.
Moderna's coronavirus vaccine is in late-stage human trials, which will test its efficacy and safety in 30,000 people. The Massachusetts-based company previously said it could expect results as early as October.
"We are investing in the development and manufacture of the top six vaccine candidates to ensure rapid delivery. The military is ready to go, they're ready to deliver a vaccine to Americans as soon as one is fully approved by the FDA and we're very close to that approval," Trump said during a press conference at the White House.
The U.S. Department of Health and Human Services previously said it would pay Pfizer and biotech firm BioNTech $1.95 billion to produce and deliver 100 million doses of their Covid-19 vaccine with the option to acquire 500 million additional doses. HHS later announced it would give Johnson & Johnson more than $1 billion for 100 million doses with the option for an additional 200 million.
HHS also struck a deal with Sanofi and GlaxoSmithKline for up to $2.1 billion to develop and deliver 100 million doses of their potential coronavirus vaccine with the option to acquire an additional 500 million doses.
The deals are part of the Trump administration's efforts to accelerate the development, manufacturing and distribution of vaccines and treatments to fight the coronavirus under the program called Operation Warp Speed.
Earlier on Tuesday, HHS Secretary Alex Azar told ABC's "Good Morning America" that the operation is on track to produce "tens of millions of doses by December of FDA-gold-standard vaccine and hundreds of millions of doses as we go into the new year."
"We appreciate the confidence of the U.S. government in our mRNA vaccine platform and the continued support," Moderna CEO Stephane Bancel said in a press release.
Bancel said on Moderna's second-quarter earnings call on Aug. 5 that the company would price its vaccine "well-below value" during the pandemic period and will price it at market value once the virus is under control.
— CNBC's Berkeley Lovelace Jr. contributed to this report.